Skip to main content

Table 3 Multivariate survival analysis of patients stratified according to 8 cycles of treatment for overall survival

From: Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?

 

Univariate COX regression

Multivariats logistic regression

Hazard ratio

95 % Cl

p value

Hazard ratio

95 % Cl

p value

Sex (man vs woman)

1.13

0.62–2.04

0.7

   

Age (≥70 years vs <70 years)

1.22

0.65–2.23

0.53

   

T stage (4 vs 1–3)

1.77

0.79–3.97

0.17

1.21

0.51–2.89

0.67

N stage (2 vs 1)

1.31

0.73–2.37

0.37

   

Histo-pathological grade (poor differentiated vs. well, moderated differentiated)

1.51

0.78 –5.23

0.35

   

Site (right vs left)

1.1

0.61–1.98

0.76

   

Pre-operative CEA (≥ 5 vs. < 5)

0.9

0.46–1.75

0.76

   

Performance status (1 and 2 vs.0)

2.08

0.93–4.66

0.08

1.91

0.83–4.40

0.13

FOLFOX cycles (≥8 vs <8)

0.54

0.30–0.99

0.043

0.52

0.28–0.97

0.038

Lymph nodes (≥12 vs. <12)

3.1

0.75–12.89

0.12

2.9

0.68–12.31

0.15

Time to treatment (≥8 vs <8 weeks)

1.71

0.61–4.79

0.31

   

Perforation or obstruction

1.92

0.99–3.73

0.053

1.41

0.68–2.93

0.36